First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2021-03-08
Target enrollment:
Participant gender:
Summary
TP-0184 is a potent inhibitor of ALK2 or ACRV1 kinase, a constitutively active
serine/threonine receptor kinase due to activating mutations or upregulated upstream
signaling pathways. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics,
and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and
dose-limiting toxicities (DLTs) of oral TP-0184 administered once weekly for 4 weeks in
patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Oncology, Inc Tolero Pharmaceuticals, Inc.